美金刚与多奈哌齐合用对帕金森痴呆患者MoCA、ADL与血清CRP、PARK7的影响

Influence of memantine combined with donepezil on MoCA, ADL and serum CRP, PARK7 in patients with Parkinson’s disease

目的研究分析美金刚与多奈哌齐合用对帕金森痴呆患者MoCA、ADL与血清CRP、PARK7的影响.方法选取本院收治的89例行帕金森痴呆患者进行研究,将所选患者按照治疗方法的不同随机分为研究组49例与对照组40例.对照组患者给予多奈哌齐进行治疗,研究组在对照组基础上联合美金刚进行治疗.回顾性分析两组患者的临床资料,对比分析两组患者临床疗效、认知功能以及日常生活能力的具体情况,并记录治疗期间不良反应发生情况.结果对照组总有效率为77.50%,研究组总有效率为95.92%,研究组总有效率高于对照组(P<0.05);治疗12周后,两组患者UPDRS总评分、MMSE评分、MoCA评分、ADL评分均较前明显改善.研究组UPDRS总评分低于对照组,MMSE评分、MoCA评分、ADL评分高于对照组,两组对比存在明显差异(P<0.05);治疗12周后,两组患者血清CRP、PARK7、NT-3水平均较前明显改善.研究组血清CRP、PARK7水平低于对照组,NT-3水平高于对照组,两组对比存在明显差异(P<0.05);对照组患者治疗后的不良反应发生率(12.50%)高于研究组患者(12.24%),但两组比较无明显差异(P>0.05).结论美金刚与多奈哌齐合用对帕金森痴呆患者具有良好的临床疗效,可以有效改善帕金森痴呆患者行为功能以及认知功能,并明显降低患者血清CRP、PARK7水平,提高了NT-3水平,且安全性较高,可作为帕金森痴呆患者首选的治疗方案.

Objective To investigate the influence of memantine combined with donepezil on MoCA, ADL and serum CRP, PARK7 in patients with Parkinson’s disease. Methods 90 Parkinson’s disease in our hospital were selected and divided into the observation group(49 cases) and the control group(40 cases), according to treatment methods. The control group was given donepezil treatment, and the observation group was given memantine combined with donepezil treatment. Clinical data of the two groups were retrospectively analyzed, the clinical effect, cognitive function, ADL of the two groups were compared and analyzed. The adverse reactions during the treatment were recorded. Results Total effective rate of the observation group(77.50%) was significantly higher than that of the control group(95.92%)(P<0.05). At 12 weeks after treatment, UPDRS total score, MMSE, MoCA and ADL scores of the two groups were significantly improved. The UPDRS total score of the observation group was lower than that of the control group. MMSE, MoCA, ADL scores were higher than those of the control group. The difference was statistically significant(P<0.05). At 12 weeks after treatment, serum CRP, PARK7, NT-3 levels were significantly improved. Serum CRP, PARK7 levels in the observation group were lower than those in the control group. The serum NT-3 level was higher than that in the control group(P<0.05). The adverse reaction rate of the control group(12.50%)was higher than that in the observation group(12.24%)(P>0.05). Conclusion Memantine combined with donepezil in patients with Parkinson’s disease have better clinical effect, which can effectively improve the illocutionary function and cognitive function, reduce the serum CRP, PARK7 levels and increase the serum NT-3 level.